Novavax moving to crack egg-based flu vaccine market

In a bid to offer an alternative to the chicken egg-based influenza vaccine market, Novavax has launched a Phase III trial of a seasonal vaccine that is manufactured using an insect cell baculovirus system.

The technology, which has received financial support from the Biomedical Advanced Research and Development Authority (BARDA), is consistent with the goals of an Executive Order on modernizing influenza vaccines signed by President Donald Trump last month (see “Trump Administration to Modernize Flu Vaccines via Government Buying Power”)...